Open Label 3 dose regimens of AT2220 in Patients with Pompe Disease

• Research type

  Research Study

• Full title

  An Open-Label, Multicenter, Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Dosing Regimens og Oral AT2220 in Patients with Pompe Disease

• IRAS ID

  1255

• Contact name

  Stephen Waldek

• Contact email

  steve.waldek@srft.nhs.uk

• Sponsor organisation

  Amicus Therapeutics Inc

• Eudract number

  2008-002302-18

• Clinicaltrials.gov Identifier

  NCT00688597

• Research summary

  Research Summary not published at request of researcher

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  08/H1004/154

• Date of REC Opinion

  9 Dec 2008

• REC opinion

  Further Information Favourable Opinion